CSL (ASX:CSL) has forecasted its FY24 NPATA to fall within an approximate range of $2.9 billion to $3.0 billion, accounting for constant currency.

The company declared a final fully franked dividend of US$1.29 per share.

CSL reported a net profit after tax of A$2.19 billion for the 12 months ended 30 June 2023, increasing by 8% based on a constant currency basis.

The firm announced revenues of $13.31 billion for the financial year, marking an increase of 31% at constant currency.

Looking forward, CSL expects another strong year for its Seqirus division, given the high demand for its differentiated products.

Also, CSL predicts continuous robust growth in its immunoglobulins franchise following record plasma collections in the previous financial year, FY23.

CSL is a biotechnology company known for its specialty biotherapeutics and influenza vaccines.